Performance characteristics of the ultrasound strategy during incidence screening in the UK collaborative trial of ovarian cancer screening (UKCTOCS)

Kalsi, Jatinderpal, Gentry‐maharaj, Aleksandra, Ryan, Andy, Singh, Naveena, Burnell, Matthew, Massingham, Susan, Apostolidou, Sophia, Sharma, Aarti, Williamson, Karin, Seif, Mourad, Mould, Tim, Woolas, Robert, Dobbs, Stephen, Leeson, Simon, Fallowfield, Lesley, Skates, Steven J., Parmar, Mahesh, Campbell, Stuart, Jacobs, Ian, McGuire, Alistair ORCID: 0000-0002-5367-9841 and Menon, Usha (2021) Performance characteristics of the ultrasound strategy during incidence screening in the UK collaborative trial of ovarian cancer screening (UKCTOCS). Cancers, 13 (4). ISSN 2072-6694

Text (Performance Characteristics of the Ultrasound Strategy during Incidence Screening in the UK Collaborative Trial of Ovarian Cancer Screening) - Published Version Available under License Creative Commons Attribution. Download (994kB)

• Scopus publication
• Author

Abstract

Randomised controlled trials of ovarian cancer (OC) screening have not yet demonstrated an impact on disease mortality. Meanwhile, the screening data from clinical trials represents a rich resource to understand the performance of modalities used. We report here on incidence screening in the ultrasound arm of UKCTOCS. 44,799 of the 50,639 women who were randomised to annual screening with transvaginal ultrasound attended annual incidence screening between 28 April 2002 and 31 December 2011. Transvaginal ultrasound was used both as the first and the second line test. Participants were followed up through electronic health record linkage and postal questionnaires. Out of 280,534 annual incidence screens, 960 women underwent screen‐positive surgery. 113 had ovarian/tubal cancer (80 invasive epithelial). Of the screen‐detected invasive epithelial cancers, 37.5% (95%CI: 26.9–49.0) were Stage I/II. An additional 52 (50 invasive epithelial) were diagnosed within one year of their last screen. Of the 50 interval epithelial cancers, 6.0% (95%CI: 1.3–16.5) were Stage I/II. For detection of all ovarian/tubal cancers diagnosed within one year of screen, the sensi-tivity, specificity, and positive predictive values were 68.5% (95%CI: 60.8–75.5), 99.7% (95%CI: 99.7– 99.7), and 11.8% (95%CI: 9.8–14) respectively. When the analysis was restricted to invasive epithelial cancers, sensitivity, specificity and positive predictive values were 61.5% (95%CI: 52.6–69.9); 99.7% (95%CI: 99.7–99.7) and 8.3% (95%CI: 6.7–10.3), with 12 surgeries per screen positive. The low sensitivity coupled with the advanced stage of interval cancers suggests that ultrasound scanning as the first line test might not be suitable for population screening for ovarian cancer. Trial registration: ISRCTN22488978. Registered on 6 April 2000.

Item Type:	Article
Official URL:	https://www.mdpi.com/journal/cancers
Additional Information:	© 2021 The Authors
Divisions:	Health Policy
Subjects:	R Medicine > RA Public aspects of medicine R Medicine > RG Gynecology and obstetrics
Date Deposited:	03 Mar 2021 13:27
Last Modified:	09 Nov 2024 02:51
URI:	http://eprints.lse.ac.uk/id/eprint/108943

Actions (login required)

View Item